Clinical Trial Update: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and efficacy of a recombinant human FGF21-Fc fusion protein for non-alcoholic steatohepatitis is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) (FGF21-Fc fusion protein)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Non-alcoholic Steatohepatitis | Phase 2 | Status: RECRUITING